[go: up one dir, main page]

SK92899A3 - Use of angiotensin ii antagonists to treat symptomatic heart failure - Google Patents

Use of angiotensin ii antagonists to treat symptomatic heart failure Download PDF

Info

Publication number
SK92899A3
SK92899A3 SK928-99A SK92899A SK92899A3 SK 92899 A3 SK92899 A3 SK 92899A3 SK 92899 A SK92899 A SK 92899A SK 92899 A3 SK92899 A3 SK 92899A3
Authority
SK
Slovakia
Prior art keywords
carbon atoms
alkyl
hydrogen
phenyl
nhso
Prior art date
Application number
SK928-99A
Other languages
English (en)
Slovak (sk)
Inventor
Polly A Beere
Paul I Chang
Bertram Pitt
Ewa J Rucinska
Robert Segal
Divakar Sharma
Duane B Snavely
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9704197.4A external-priority patent/GB9704197D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of SK92899A3 publication Critical patent/SK92899A3/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
SK928-99A 1997-01-10 1998-01-07 Use of angiotensin ii antagonists to treat symptomatic heart failure SK92899A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3492797P 1997-01-10 1997-01-10
GBGB9704197.4A GB9704197D0 (en) 1997-02-28 1997-02-28 Method for reducing mortality with an angiotensin 11 antagonist
PCT/US1998/000534 WO1998030216A1 (en) 1997-01-10 1998-01-07 Use of angiotensin ii antagonists to treat symptomatic heart failure

Publications (1)

Publication Number Publication Date
SK92899A3 true SK92899A3 (en) 2000-08-14

Family

ID=26311085

Family Applications (1)

Application Number Title Priority Date Filing Date
SK928-99A SK92899A3 (en) 1997-01-10 1998-01-07 Use of angiotensin ii antagonists to treat symptomatic heart failure

Country Status (18)

Country Link
EP (1) EP0966282B1 (zh)
JP (1) JP2000508347A (zh)
KR (1) KR20000070046A (zh)
CN (1) CN1249682A (zh)
AT (1) ATE243515T1 (zh)
AU (1) AU729881B2 (zh)
CA (1) CA2277018C (zh)
DE (1) DE69815822T2 (zh)
DK (1) DK0966282T3 (zh)
EA (1) EA199900635A1 (zh)
EE (1) EE9900278A (zh)
ES (1) ES2200310T3 (zh)
HU (1) HUP0000108A2 (zh)
IL (1) IL130599A0 (zh)
NO (1) NO993399L (zh)
PT (1) PT966282E (zh)
SK (1) SK92899A3 (zh)
WO (1) WO1998030216A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
SE9902597D0 (sv) * 1999-07-06 1999-07-06 Astra Ab New use
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
NZ517468A (en) 1999-08-30 2004-02-27 Aventis Pharma Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US6833381B2 (en) * 2000-02-18 2004-12-21 Takeda Chemical Industries, Ltd. TNF-α inhibitors
JP2005126338A (ja) * 2003-10-21 2005-05-19 Boehringer Ingelheim Pharma Gmbh & Co Kg 心不全治療剤
AR078107A1 (es) * 2009-08-31 2011-10-12 Sanofi Aventis Uso de irbesartan para la preparacion de un medicamento para la prevencion de la hospitalizacion por insuficiencia cardiaca
RS65037B1 (sr) * 2013-08-26 2024-02-29 Novartis Ag Lečenje kardiovaskularnih oboljenja
CA3029630A1 (en) 2016-06-29 2018-01-04 Universite De Montreal Biarylmethyl heterocycles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9609066A (pt) * 1995-06-07 1999-01-26 Searle & Co Antagonista aldoesterone epoxi-esteroidal e terapia de combinação de antagonista angiotensina ii para tratamento de deficiência do coração

Also Published As

Publication number Publication date
JP2000508347A (ja) 2000-07-04
IL130599A0 (en) 2000-06-01
WO1998030216A1 (en) 1998-07-16
DE69815822D1 (de) 2003-07-31
CA2277018C (en) 2006-10-03
ES2200310T3 (es) 2004-03-01
EA199900635A1 (ru) 2000-02-28
DE69815822T2 (de) 2004-05-06
EE9900278A (et) 2000-02-15
DK0966282T3 (da) 2003-09-29
EP0966282A1 (en) 1999-12-29
ATE243515T1 (de) 2003-07-15
CN1249682A (zh) 2000-04-05
HUP0000108A2 (hu) 2001-04-28
AU729881B2 (en) 2001-02-15
AU6021898A (en) 1998-08-03
CA2277018A1 (en) 1998-07-16
NO993399L (no) 1999-09-09
NO993399D0 (no) 1999-07-09
KR20000070046A (ko) 2000-11-25
PT966282E (pt) 2003-10-31
EP0966282B1 (en) 2003-06-25

Similar Documents

Publication Publication Date Title
US6201002B1 (en) Method for reducing mortality with an angiotensin II antagonist
Marino et al. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects
JPH11228410A (ja) イミダゾールアンジオテンシン−ii受容体拮抗薬からなる慢性腎不全治療剤
US6300356B1 (en) Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist
JP2004523569A (ja) 抗高血圧薬とコレステロール吸収阻害薬の併用療法
SK92899A3 (en) Use of angiotensin ii antagonists to treat symptomatic heart failure
JP2009500361A (ja) ニフェジピンおよび/またはニソルジピン並びにアンジオテンシンiiアンタゴニストからなる有効成分の組合せを含む医薬投与形
US20190241545A1 (en) 1,3-Dihydroimidazole-2-Thione Derivatives for Use in the Treatment of Pulmonary Arterial Hypertension and Lung Injury
JP2001089393A (ja) 脳血管障害の再発予防剤および脳血管障害の後遺症の改善・進展抑制剤
US20030073705A1 (en) Method of treatment
Pereira et al. A novel Ca²+ channel antagonist reverses cardiac hypertrophy and pulmonary arteriolar remodeling in experimental pulmonary hypertension
AU2002350832B2 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
JP2006517557A (ja) 脳卒中発作予防のための、アセチルサリチル酸およびアンジオテンシンii拮抗薬と組み合わせたジピリダモールの使用
CZ244899A3 (cs) Použití antagonistů receptorů angiotensinu II
CN100558359C (zh) 肾小球病治疗剂
JP2007538030A (ja) 有機化合物の組合せ剤
KR20040032969A (ko) 안지오텐신 ii 수용체 길항제를 함유하는 의약 조성물
JP2008133229A (ja) 医薬組成物
KR20070084315A (ko) 울혈성 심장기능상실 치료용 pde v 억제제의 사용 방법
JP2023524154A (ja) 脳アミノペプチダーゼa阻害剤と、利尿薬と、全身性レニン-アンギオテンシン系の遮断薬とを含む医薬組合せ
CN120571025A (zh) 一种含有ARNi和钙离子拮抗剂的药物组合物
WO2006002983A1 (en) Combination of organic compounds
EA044411B1 (ru) Антагонист рецептора ангиотензина ii для предотвращения или лечения системных заболеваний у котов